問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Digestive System Department

Division of Thoracic Medicine

更新時間:2023-09-19

謝政毅Hsieh, Cheng-I
  • Co-Principal Investigator
  • Clinical Trial Experience (year) 13 years

篩選

List

19Cases

2022-12-23 - 2026-12-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2025-09-22 - 2029-03-18

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2024-01-22 - 2027-05-27

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting1Sites

Recruiting11Sites

2024-11-15 - 2027-02-16

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-11-27 - 2028-05-29

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2016-11-01 - 2025-12-31

Others

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated11Sites

楊再勝
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2021-01-01 - 2024-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2022-04-15 - 2023-10-11

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2018-05-30 - 2022-12-31

Phase II

An Open-label Phase 2 Trial of Dual TORC1/TORC2 Inhibitor ATG-008 in HBV+ Advanced Hepatocellular Carcinoma (HCC) Subjects Who Have Received at Least One Prior Line of Systemic Therapy (TORCH)
  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    ATG-008

Participate Sites
6Sites

Recruiting5Sites

楊再勝
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

1 2